COVID‐19 IN PATIENTS WITH PLAQUE PSORIASIS WHO ARE ON BIOLOGIC THERAPY WITH SECUKINUMAB
Jelena Petkovic-Dabic*, Renata Tamburic and Sasa Dabic
ABSTRACT
Psoriasis is a chronically recurrent inflammatory skin disease that affects about 2-3% of the world's population. Based on the clinical picture, we distinguish between chronic plaque psoriasis, droplet psoriasis, nail psoriasis, inverse psoriasis, localized and generalized pustular psoriasis and erythrodermic psoriasis. In more than 20% of patients with plaque psoriasis, a clinical picture of moderate to severe disease develops. Based on the association of HLA antigen with the age of onset of psoriasis, we distinguish two forms of the disease, type I psoriasis and type II psoriasis. Type I disease occurs before age 40, is inherited, is more severe, and is associated with a significantly higher frequency of HLA Cw6 antigen. Type II psoriasis begins between the ages of 50 and 60, occurs sporadically, shows no association with HLA genes, and is milder in clinical course.[1] The paper presents a case report of a patient who was exposed to coronavirus disease (COVID-19) during treatment with plaque psoriasis with the biological drug secukinumab.
[Full Text Article] [Download Certificate]